|
|
||||||||




* Department of Geriatric and Respiratory Medicine and
Department of Anatomic Pathology, Tohoku University School of Medicine, Sendai, Japan;
Department of Pathology and
Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan;
¶ Department of Experimental Immunology, Institute of Development, Aging, and Cancer, Tohoku University, Sendai, Japan;
|| Laboratory of Lung Immunology and Host Defense, Department of Pediatrics, University of Pittsburgh, Pittsburgh, PA 15213; and
# Translational Research, Molecular Medicine Institute, University of Pittsburgh School of Medicine, Pittsburgh, PA 15219
In this study, we examined the biological action of IL-17 on human non-small cell lung cancer (NSCLC). Although IL-17 had no direct effect on the in vitro growth rate of NSCLC, IL-17 selectively augmented the secretion of an array of angiogenic CXC chemokines, including CXCL1, CXCL5, CXCL6, and CXCL8 but not angiostatic chemokines, by three different NSCLC lines. Endothelial cell chemotactic activity (as a measure of net angiogenic potential) was increased in response to conditioned medium from NSCLC stimulated with IL-17 compared with those from unstimulated NSCLC. Enhanced chemotactic activity was suppressed by neutralizing mAb(s) to CXCL1, CXCL5, and CXCL8 or to CXCR-2 but not to vascular endothelial growth factor-A. Transfection with IL-17 into NSCLC had no effect on the in vitro growth, whereas IL-17 transfectants grew more rapidly compared with controls when transplanted in SCID mice. This IL-17-elicited enhancement of NSCLC growth was associated with increased tumor vascularity. Moreover, treatment with anti-mouse CXCR-2-neutralizing Ab significantly attenuated the growth of both neomycin phosphotransferase gene-transfected and IL-17-transfected NSCLC tumors in SCID mice. A potential role for IL-17 in modulation of the human NSCLC phenotype was supported by the findings that, in primary NSCLC tissues, IL-17 expression was frequently detected in accumulating and infiltrating inflammatory cells and that high levels of IL-17 expression were associated with increased tumor vascularity. These results demonstrate that IL-17 increases the net angiogenic activity and in vivo growth of NSCLC via promoting CXCR-2-dependent angiogenesis and suggest that targeting CXCR-2 signaling may be a novel promising strategy to treat patients with NSCLC.
This article has been cited by other articles:
![]() |
P. Muranski, A. Boni, P. A. Antony, L. Cassard, K. R. Irvine, A. Kaiser, C. M. Paulos, D. C. Palmer, C. E. Touloukian, K. Ptak, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma Blood, July 15, 2008; 112(2): 362 - 373. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Nam, M. Terabe, M.-J. Kang, H. Chae, N. Voong, Y.-a. Yang, A. Laurence, A. Michalowska, M. Mamura, S. Lonning, et al. Transforming Growth Factor {beta} Subverts the Immune System into Directly Promoting Tumor Growth through Interleukin-17 Cancer Res., May 15, 2008; 68(10): 3915 - 3923. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yusuf, T. H. Nasti, S. K. Katiyar, M. K. Jacobs, M. D. Seibert, A. C. Ginsburg, L. Timares, H. Xu, and C. A. Elmets Antagonistic Roles of CD4+ and CD8+ T-Cells in 7,12-Dimethylbenz(a)anthracene Cutaneous Carcinogenesis Cancer Res., May 15, 2008; 68(10): 3924 - 3930. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Yusuf, T. H. Nasti, J. A. Long, M. Naseemuddin, A. P. Lucas, H. Xu, and C. A. Elmets Protective Role of Toll-like Receptor 4 during the Initiation Stage of Cutaneous Chemical Carcinogenesis Cancer Res., January 15, 2008; 68(2): 615 - 622. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xiao and S. V. Singh z-Guggulsterone, a constituent of Ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo Mol. Cancer Ther., January 1, 2008; 7(1): 171 - 180. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-J. Liu, J.-P. Tsai, C.-R. Shen, Y.-P. Sher, C.-L. Hsieh, Y.-C. Yeh, A.-H. Chou, S.-R. Chang, K.-N. Hsiao, F.-W. Yu, et al. Induction of a distinct CD8 Tnc17 subset by transforming growth factor-{beta} and interleukin-6 J. Leukoc. Biol., August 1, 2007; 82(2): 354 - 360. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Numasaki, M. Tagawa, F. Iwata, T. Suzuki, A. Nakamura, M. Okada, Y. Iwakura, S. Aiba, and M. Yamaya IL-28 Elicits Antitumor Responses against Murine Fibrosarcoma J. Immunol., April 15, 2007; 178(8): 5086 - 5098. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Xiao and S. V. Singh Phenethyl Isothiocyanate Inhibits Angiogenesis In vitro and Ex vivo Cancer Res., March 1, 2007; 67(5): 2239 - 2246. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |